FDA Approves New Generic Abortion Pill, Sparking Criticism

The Food and Drug Administration has recently authorized a generic version of mifepristone, an abortion medication. This approval has faced sharp opposition from conservatives, especially since the agency’s head, Health Secretary Robert F. Kennedy Jr., had promised a comprehensive safety review of the drug.

The manufacturer, Evita Solutions, received notification from the FDA confirming the approval of their application for mifepristone tablets—used to terminate pregnancies up to 10 weeks—just one day before a potential government shutdown.

According to the FDA, the review concluded the drug meets all necessary standards for approval. Kennedy explained that under federal law, approval is mandatory if the generic is identical to the brand-name medication.

Previously, Kennedy indicated that his department would undertake a “complete review” following a study indicating that nearly 11% of women who used mifepristone experienced serious health complications. He personally instructed FDA officials to investigate the drug’s safety and real-world outcomes.

However, critics, including Senator Josh Hawley, have expressed concern over the decision. Hawley labeled the approval “shocking” and questioned the FDA’s commitment to thorough safety assessments, citing a loss of confidence in the agency’s leadership.

This decision comes amid ongoing debates about abortion policies. Critics, including former Vice President Mike Pence, have called for Kennedy’s resignation, accusing him of betraying pro-life principles and urging the administration to reverse the approval.

Kennedy, known for his support of abortion rights, has previously expressed views favoring less government involvement in such decisions, including advocating for unrestricted abortion up to a certain point in pregnancy.